SCRT base on PI, which means there are sub-groups in the SCRT groups. So the estimation of sample size should be based on this sub-groups which are more than 2 groups. 5. In the part of withdrawal criteria, the participants who use of medication that can affect nasal symptoms will be removed out of this study. Which treatment will be applied if the nasal symptoms (like nasal congestion, rhinorrhea, nasal itching, and sneezing) affect the life quality of subject seriously and need medication to relieve the symptom? 6. In page 20, line 3, registry number in ClinicalTrials.gov is NCT02900131. But in the last line of page 2, this trial was registered with NCT03009136. Why are the registry numbers not consistent in this manuscript?
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GENERAL COMMENTS
Is there any reason why other forms of allergic rhinitis were excluded? If yes, perhaps the authors will consider explaining their selection of a single form of AR If there are references for the washout periods for these drugs, these should be inserted. Some justification for selecting one month is appropriate should be provided Here and in other places, the authors may consider using the nonNorth American spelling of "enrollment", i.e. "enrolment" How were the common allergens selected? If there is one, please provide a reference I"m concerned that the testing of Cytokines will only be performed for participants in one centre. Usually, it is advisable to not allow for any difference in how different groups of participants are handled, even though the intervention and placebo groups both will be tested in the same manner at this center. Are the "vital signs" listed any where? Cytokines will not be measured for all participants needs to be stated here as well If the cytokines testing is a nested study, then this needs to be clearly stated in the protocol What is the purpose of this pattern identification, in this context? MHK have written.." should be "MHK has written…"
VERSION 1 -AUTHOR RESPONSE
# Reviewer 1 [C] I check the registry information of this trial in www.clinicaltrials.gov and found this is a phase III RCT, which aims to gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug. Do you want to commercialize SCRT granules? In my opinion, the sample size of phase III clinical trials should not only satisfied the requirements of statistics, but also achieved the requirement of drug-related laws. Please provide relevant laws and regulations for Phase III clinical trials in Korea and the English edition.
[A] In Korea, phase III clinical trials aim to gather more information about safety and effectiveness by studying different populations and different dosages of the drug, as you mentioned. they are enforced after efficacy has been appropriately established. SCRT is a drug that has already been clinically proven to have therapeutic benefits for all types of rhinitis(e.g., non-allergic and allergic rhinitis). Since we have already confirmed the clinically valid results through case reports, we planned a pilot Phase III clinical trial for perennial allergic rhinitis, a specific form of the condition that is included under the rhinitis indication for this drug. This study is classified as an investigator initiated trial, which is not equivalent to regular commercial clinical trials. On the clinical trials.gov web page, there was no section to indicate investigator initiated so we selected the most appropriate, which was Phase III clinical trials.
[C] In page 8, line 2. The inclusion criteria did not describe the specific symptoms of PAR, such as ≥ 9 months nasal symptoms. All the inclusion criteria cannot identified the seasonal allergic rhinitis and perennial allergic precisely. In addition, the diagnostic criteria of PAR are not specific and literature supported. Please provide the diagnostic criteria of PAR and the source of literature.
[A] Thank you for your comment. A universally accepted definition of PAR does not exist. Most often, it is defined as a disease that persists for longer than 9 months each year and produces two or more of the following symptoms: serous or seromucus hypersecretions, nasal blockage caused by a swollen nasal mucosa, or sneezing paroxysms [1] . These criteria of PAR were stated in our inclusion criteria (2) and (3).
[1] David P. Skoner. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S2-8.
[C] In this protocol, the author described the pattern identification (PI) of AR, but all the recruited participants were diagnosed as PAR which is not consistent with context. The reader will be confused whether the PI questionnaire is applied in the assessment of AR or PAR, even though there are several common symptoms between AR and PAR. This point should be clarified.
[A] We agree with your comment and thus have clarified this point in the revised manuscript ("Pattern identification questionnaire for allergic rhinitis" section of the Methods).
[C] The second aim of this trial was to investigate the efficacy of SCRT base on PI, which means there are sub-groups in the SCRT groups. So the estimation of sample size should be based on this sub-groups which are more than 2 groups.
[A] Thank you for your comment. The nasal endoscopy index for PI classifies patients with AR into two groups. PI by the clinician classifies patients with AR into three subgroups based on body and nasal conditions. Therefore, it would be difficult to predict or pre-determine the number of patients in each subgroup. The first aim of the study was to investigate the short-and long-term efficacy and safety of SCRT treatment in patients with PAR. Thus, we estimated the sample size based on the first aim (primary outcome: TNSS).
[C] In the part of withdrawal criteria, the participants who use of medication that can affect nasal symptoms will be removed out of this study. Which treatment will be applied if the nasal symptoms (like nasal congestion, rhinorrhea, nasal itching, and sneezing) affect the life quality of subject seriously and need medication to relieve the symptom?
[A] We did not plan for rescue medicine in this study. The protocol was approved by the IRB without this inclusion. Antihistamines are generally used as rescue medicine in allergic rhinitis clinical trials; however, the use of such medications can confound the results. In order to obtain more accurate results, we decided that excluding participants who use these medications would be more suitable than setting a rescue medicine protocol.
[C] In page 20, line 3, registry number in ClinicalTrials.gov is NCT02900131. But in the last line of page 2, this trial was registered with NCT03009136. Why are the registry numbers not consistent in this manuscript? [A] NCT03009136 is the right number and we have corrected this error in the revised manuscript. We apologize for the confusion.
